Augustine Therapeutics is proud to participate in the Clinical Trials in Rare Diseases Europe 2024 organized by Arena, to be held on November 19th and 20th 2024 at the Sheraton Brussels Airport Hotel, Brussels (Belgium)
This 2-day event will explore the challenges in clinical trials for orphan drug and rare disease trials in Europe, bringing together clinical operations professionals from across multiple therapeutic areas to discuss common obstacles and solutions.
Our CMO, Dr. Carl Bjartmar, will be speaking on November 20th at 11.15am CET, highlighting the ‘Challenges and Opportunities in Rare Disease Clinical Development’.
Augustine Therapeutic is currently advancing AGT-100216, a highly selective, orally bioavailable and safe HDAC6 inhibitor clinical candidate towards First-in-man clinical trial as a potential treatment for rare inherited neuropathy disorders like Charco-Marie-Tooth diseases.
Find out details of the event and agenda here: Click Here
